| Property | Value |
|---|---|
| Protein Name | Peroxiredoxin 1 |
| Gene | PRDX1 |
| UniProt ID | Q06830 |
| PDB ID | 1XCC, 2Z9S, 5B6T, 4XWX |
| Molecular Weight | ~22 kDa |
| Subcellular Localization | Cytoplasm, nucleus, mitochondria |
| Protein Family | Peroxiredoxin family (2-Cys typical) |
| Expression | Ubiquitous, high in brain |
Peroxiredoxin 1 (PRDX1) is a 199-amino acid member of the typical 2-Cys peroxiredoxin family that serves as a central component of cellular antioxidant defense. Discovered as a ubiquitous antioxidant enzyme, PRDX1 has evolved from a simple H2O2-scavenging protein to a critical regulator of redox signaling, cellular stress responses, and neurodegenerative disease pathogenesis[1].
PRDX1 possesses unique biochemical properties that distinguish it from other antioxidant enzymes. Its ability to undergo hyperoxidation (overoxidation of the catalytic cysteine to cysteine-sulfinic acid) and be regenerated by sulfiredoxin represents a sophisticated redox regulatory mechanism. This "peroxidase-thiolspecific peroxidase" function is essential for maintaining cellular reactive oxygen species (ROS) homeostasis while permitting redox signaling.
In the nervous system, PRDX1 plays indispensable roles in protecting neurons from oxidative damage, regulating inflammatory responses, and maintaining synaptic function. Its dysregulation has been strongly implicated in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis. This has made PRDX1 an attractive target for neuroprotective therapeutic strategies.
The PRDX1 protein exhibits sophisticated structural features that enable its diverse functions[2]:
N-Terminal Resolving Cysteine (Cys52): The first conserved cysteine that forms a disulfide bond with the C-terminal cysteine during the catalytic cycle. This residue is essential for peroxidase activity.
C-Terminal Resolving Cysteine (Cys173): The second critical cysteine that forms an intersubunit disulfide bond in the dimeric protein. This forms the characteristic 2-Cys peroxiredoxin disulfide.
Active Site FVCP Motif (aa 49-52): The conserved motif containing the N-terminal resolving cysteine. This motif is critical for nucleophilic attack on peroxides.
Thioredoxin Fold: The characteristic three-dimensional structure shared with thioredoxin and glutaredoxin families, providing the structural basis for redox activity.
Decameric Oligomerization: PRDX1 forms toroidal decamers (doughnut-shaped 10-mers) composed of five dimers. This oligomerization modulates its chaperone function.
Phosphorylation Sites: Multiple regulatory phosphorylation sites (Tyr194, Ser32) that modulate PRDX1 function in response to cellular signaling.
The catalytic cycle involves:
PRDX1 has a unique ability to become hyperoxidized (Cys-SO2/SO3) under high oxidative stress, which:
This switch allows PRDX1 to transition from a peroxide detoxifier to a stress-responsive chaperone.
PRDX1 performs multiple essential functions in neurons and glia:
Peroxide Reduction: PRDX1 efficiently detoxifies H2O2 and organic peroxides (t-butyl hydroperoxide, lipid peroxides). Its Km for H2O2 is in the micromolar range, making it a high-affinity peroxidase.
Redox Signaling Modulation: Unlike simple scavengers, PRDX1 modulates cellular signaling by controlling H2O2 levels at the site of production, particularly near receptor tyrosine kinases and transcription factors.
Protein Protection: PRDX1 prevents oxidative damage to proteins by reducing protein hydroperoxides before they cause irreversible oxidation of amino acid residues.
DNA Protection: Guards against oxidative DNA damage by maintaining nuclear redox balance.
When hyperoxidized, PRDX1 transitions to a molecular chaperone:
PRDX1 regulates multiple signaling pathways:
In glial cells (microglia, astrocytes):
PRDX1 has complex, context-dependent effects on apoptosis:
PRDX1 dysfunction is strongly implicated in AD pathogenesis[3]:
Oxidative Stress
AD brain shows characteristic oxidative stress markers:
Amyloid Pathology
Amyloid-beta (Aβ) induces PRDX1 oxidation:
Tau Pathology
PRDX1 affects tau phosphorylation and aggregation:
Synaptic Dysfunction
PRDX1 loss affects synaptic compartments:
Therapeutic Implications
PRDX1 is implicated in multiple aspects of PD pathogenesis[4]:
Dopaminergic Neuron Protection
PRDX1 protects SNc neurons:
Alpha-Synuclein Interaction
PRDX1 modulates alpha-synuclein (α-syn) aggregation:
Genetic Susceptibility
PRDX1 variants may modify PD risk:
Neuroinflammation
PRDX1 modulates microglial responses:
PRDX1 alterations in ALS:
Motor Neuron Vulnerability
Oxidative Stress
Protein Aggregation
PRDX1 in demyelinating disease:
| Approach | Status | Notes |
|---|---|---|
| Nrf2 activators | Phase 2 | Increase PRDX1 expression |
| Sulforaphane | Phase 1-2 | Dietary Nrf2 activator |
| Bardoxolone methyl | Phase 2 | Nrf2 activator in MS |
| Gene therapy | Preclinical | AAV-PRDX1 |
Small Molecules
Protein/Peptide Therapies
Gene Therapy
Combination Approaches
Nrf2-ARE Pathway
PRDX1 is both upstream and downstream of Nrf2:
ASK1-JNK/p38 Pathway
NF-κB Pathway
Rhee et al., Peroxiredoxin function and mechanism (2005) — Comprehensive review of peroxiredoxin biology
Wood et al., Peroxiredoxin structures (2003) — Structural basis for function
Kang et al., PRDX1 in Alzheimer's disease (2018) — Evidence for PRDX1 in AD pathogenesis
Liu et al., PRDX1 in Parkinson's disease models (2020) — PD model studies
Chen et al., Neuroprotective function of PRDX1 (2009) — Neuronal protection mechanisms
Kim et al., PRDX1 in apoptosis (2008) — Pro- and anti-apoptotic functions
Sayeed et al., PRDX1 in oxidative stress (2006) — Critical role in cell survival
Yang et al., PRDX1 in synapse function (2017) — Synaptic protection
Liu et al., PRDX1 redox signaling (2017) — Redox signaling mechanisms
Jia et al., PRDX1 and tau pathology (2019) — Tau relationship
Yeh et al., PRDX1 in neuroinflammation (2015) — Glial cell functions
Hu et al., PRDX1 and aging (2019) — Age-related changes
Neumann et al., PRDX1 oxidative stress response (2022) — Recent advances
Zhang et al., PRDX1 in AD models (2021) — Therapeutic potential
Kato et al., PRDX1 antioxidant therapy (2020) — Therapeutic strategies
Park et al., PRDX1 in neurodegeneration (2019) — Comprehensive review
Fischer et al., Redox signaling in CNS (2011) — CNS redox biology
Pak et al., PRDX1 catalytic mechanism (2004) — Enzyme mechanism
Wang et al., PRDX1 in cellular stress (2008) — Cellular functions
Perez et al., Peroxiredoxin family in neurodegeneration (2021) — Family overview